Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

Willemze, 2014, High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial, J Clin Oncol, 32, 219, 10.1200/JCO.2013.51.8571 Löwenberg, 2011, Cytarabine dose for acute myeloid leukemia, N Engl J Med, 364, 1027, 10.1056/NEJMoa1010222 Li, 2014, High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis, PLoS One, 9 Kantarjian, 2021, Acute myeloid leukemia: current progress and future directions, Blood Cancer J, 11, 41, 10.1038/s41408-021-00425-3 Löwenberg, 2009, High-dose daunorubicin in older patients with acute myeloid leukemia, N Engl J Med, 361, 1235, 10.1056/NEJMoa0901409 Fernandez, 2009, Anthracycline dose intensification in acute myeloid leukemia, N Engl J Med, 361, 1249, 10.1056/NEJMoa0904544 Burnett, 2015, A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients, Blood, 125, 3878, 10.1182/blood-2015-01-623447 Devillier, 2015, Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics, Am J Hematol, 90, E29, 10.1002/ajh.23884 Mandelli, 2009, Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10, J Clin Oncol, 27, 5397, 10.1200/JCO.2008.20.6490 Pautas, 2010, Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study, J Clin Oncol, 28, 808, 10.1200/JCO.2009.23.2652 Gandhi, 1993, Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy, J Clin Oncol, 11, 116, 10.1200/JCO.1993.11.1.116 Holowiecki, 2004, Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study, Leukemia, 18, 989, 10.1038/sj.leu.2403336 Holowiecki, 2012, Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study, J Clin Oncol, 30, 2441, 10.1200/JCO.2011.37.1286 Jain, 2016, Cladribine combined with idarubicin and ara-C (CLIA) as a frontline and salvage treatment for young patients (≤65 yrs) with acute myeloid leukemia, Blood, 128, 10.1182/blood.V128.22.1639.1639 DiNardo, 2020, Azacitidine and venetoclax in previously untreated acute myeloid leukemia, N Engl J Med, 383, 617, 10.1056/NEJMoa2012971 Wei, 2020, Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial, Blood, 135, 2137, 10.1182/blood.2020004856 DiNardo, 2020, 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial, Lancet Haematol, 7, e724, 10.1016/S2352-3026(20)30210-6 Patel, 2019, Ultra-rapid reporting of GENomic targets (URGENTseq): clinical next-generation sequencing results within 48 Hours of sample collection, J Mol Diagn, 21, 89, 10.1016/j.jmoldx.2018.08.002 Xu, 2017, How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia?, Clin Lab Med, 37, 787, 10.1016/j.cll.2017.07.004 Cheson, 2003, Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, J Clin Oncol, 21, 4642, 10.1200/JCO.2003.04.036 Thall, 1995, Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes, Stat Med, 14, 357, 10.1002/sim.4780140404 Chua, 2020, Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy, J Clin Oncol, 38, 3506, 10.1200/JCO.20.00572 Stone, 2017, Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation, N Engl J Med, 377, 454, 10.1056/NEJMoa1614359